Chemokine receptors, or CCRs, are cytokine receptors that can be found on the surface of some cells and interact with specific chemokines. Mammals have 19 different chemokine receptors that have been identified. They are all members of a large protein family known as G protein-coupled receptors because they each have a 7-transmembrane (7TM) structure and couple to G-protein for signal transduction inside of a cell. Chemokine receptors cause an increase in intracellular calcium (Ca2+) ions after interacting with their particular chemokine ligands (calcium signaling).Cell responses result from this, and one of them is the beginning of the chemotaxis process, which directs the cell to the desired area of the organism. The four different subfamilies of chemokines that chemokine receptors bind are grouped into four families: CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors, and XC chemokine receptors. Some chemokine receptors act as entry points for HIV, while others support inflammatory conditions and cancer.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V51091 | PF-07054894 | 2413693-96-4 | PF-07054894 is a potent CCR6 antagonist. | |
V3261 | PF-4136309 (INCB-8761) | 1341224-83-6 | PF-4136309 (formerly known as INCB8761) is a novel, potent, selective, and orally bioavailable small molecule CCR2 antagonist with IC50 values of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2, respectively. | |
V51101 | Plozalizumab | 1610761-46-0 | Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. | |
V5046 | RS 102895 HCl | 1173022-16-6 | RS-102895 HCl (RS 102895), the hydrochloride salt of RS102895, is a novel and potent chemokine receptor CCR2 antagonist anticancer activity. | |
V51094 | SB-328437 | 247580-43-4 | SB-328437 is a potent, selective, non-peptide CCR3 antagonist (inhibitor) with IC50 of 4.5 nM. | |
V74755 | SB-649701 | 935262-95-6 | SB-649701 is a potent human CCR8 antagonist (inhibitor) with pIC50 of 7.7. | |
V3754 | SB297006 | 58816-69-6 | SB297006 (SB-297006) is an antagonist of CCR3 (Chemokine receptor, IC50 = 39 nM) with anticancer activity. | |
V4592 | TAK-779 | 229005-80-5 | TAK-779 (TAK779) is a novel, potent and selective nonpeptide antagonist of CCR5 [C-C chemokine receptor type 5 (CCR5) receptor] and CXCR3 with potential anticancer, immunomodulatory and antiinflammatory activities. | |
V51089 | Tivumecirnon (FLX-475) | 2174938-78-2 | Tivumecirnon (FLX475) is a potent CCR4 antagonist tumor agent that blocks the regulation of anti-immune responses that effectively interferes with T cells and has anti-tumor activity. | |
V84354 | trans-J-113863 | 202796-42-7 | ||
V3651 | Vercirnon | 698394-73-9 | Vercirnon (formerly also known as CCX282-B and GSK1605786) is a novel, potent, orally bioavailable, selective antagonist of CCR9 with an IC50 of 10 nM, used in the research of inflammatory bowel diseases. | |
V51095 | Vercirnon sodium (CCX282-B; GSK-1605786A) | 886214-18-2 | CCR9 antagonist | |
V4675 | Vicriviroc maleate (SCH-417690 maleate) | 599179-03-0 | Vicriviroc maleate (formerly known as SCH 417690; SCH-D), the maleate salt of vicriviroc, is a novel, potent, selective, orally bioavailable and CNS penetrant antagonist ofCCR5entry inhibitor of HIV-1with aKiof 2.5 nM, and also inhibits HIV-1 in PBMC cells, withIC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570). | |
V74750 | ZK 756326 | 874911-96-3 | ZK756326 is a non-peptide chemokine receptor agonist (activator) that targets the CC chemokine receptor CCR8. | |
V28513 | ZK-756326 dihydrochloride | 1780259-94-0 | ZK756326 diHCl is a non-peptide chemokine receptor agonist (activator) that works on the CC chemokine receptor CCR8. |